Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1EC0

HIV-1 protease in complex with the inhibitor bea403

1EC0 の概要
エントリーDOI10.2210/pdb1ec0/pdb
関連するPDBエントリー1AJV 1AJX 1D4H 1D4I 1D4J 1EBW 1EBY 1EBZ 1EC1 1EC2 1EC3
分子名称HIV-1 PROTEASE, N,N-[2,5-O-DI-2-FLUORO-BENZYL-GLUCARYL]-DI-[1-AMINO-INDAN-2-OL] (3 entities in total)
機能のキーワードdimer, protein-inhibitor complex, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
由来する生物種Human immunodeficiency virus 1
細胞内の位置Gag-Pol polyprotein: Host cell membrane; Lipid-anchor. Matrix protein p17: Virion membrane; Lipid- anchor . Capsid protein p24: Virion . Nucleocapsid protein p7: Virion . Reverse transcriptase/ribonuclease H: Virion . Integrase: Virion : P03366
タンパク質・核酸の鎖数2
化学式量合計22296.23
構造登録者
Unge, T. (登録日: 2000-01-25, 公開日: 2002-06-26, 最終更新日: 2024-02-07)
主引用文献Lindberg, J.,Pyring, D.,Lowgren, S.,Rosenquist, A.,Zuccarello, G.,Kvarnstrom, I.,Zhang, H.,Vrang, L.,Classon, B.,Hallberg, A.,Samuelsson, B.,Unge, T.
Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy
Eur.J.Biochem., 271:4594-4602, 2004
Cited by
PubMed Abstract: HIV-1 protease is a pivotal enzyme in the later stages of the viral life cycle which is responsible for the processing and maturation of the virus particle into an infectious virion. As such, HIV-1 protease has become an important target for the treatment of AIDS, and efficient drugs have been developed. However, negative side effects and fast emerging resistance to the current drugs have necessitated the development of novel chemical entities in order to exploit different pharmacokinetic properties as well as new interaction patterns. We have used X-ray crystallography to decipher the structure-activity relationship of fluoro-substitution as a strategy to improve the antiviral activity and the protease inhibition of C2-symmetric diol-based inhibitors. In total we present six protease-inhibitor complexes at 1.8-2.3 A resolution, which have been structurally characterized with respect to their antiviral and inhibitory activities, in order to evaluate the effects of different fluoro-substitutions. These C2-symmetric inhibitors comprise mono- and difluoro-substituted benzyloxy side groups in P1/P1' and indanoleamine side groups in P2/P2'. The ortho- and meta-fluorinated P1/P1'-benzyloxy side groups proved to have the most cytopathogenic effects compared with the nonsubstituted analog and related C2-symmetric diol-based inhibitors. The different fluoro-substitutions are well accommodated in the protease S1/S1' subsites, as observed by an increase in favorable Van der Waals contacts and surface area buried by the inhibitors. These data will be used in the development of potent inhibitors with different pharmacokinetic profiles towards resistant protease mutants.
PubMed: 15560801
DOI: 10.1111/j.1432-1033.2004.04431.x
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.79 Å)
構造検証レポート
Validation report summary of 1ec0
検証レポート(詳細版)ダウンロードをダウンロード

250059

件を2026-03-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon